Employee-related Liabilities, Current of Inozyme Pharma, Inc. from 31 Dec 2019 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Inozyme Pharma, Inc. quarterly Employee-related Liabilities, Current in USD history and change rate from 31 Dec 2019 to 31 Dec 2024.
  • Inozyme Pharma, Inc. Employee-related Liabilities, Current for the quarter ending 31 Dec 2024 was $3,666,000, a 4.5% decline year-over-year.
Source SEC data
View on sec.gov
Employee-related Liabilities, Current, Quarterly (USD)
Employee-related Liabilities, Current, YoY Quarterly Change (%)

Inozyme Pharma, Inc. Quarterly Employee-related Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $3,666,000 -$172,000 -4.5% 31 Dec 2024 10-K 10 Mar 2025 2024 FY
Q4 2023 $3,838,000 +$609,000 +19% 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q2 2023 $2,682,000 +$1,003,000 +60% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $2,033,000 +$1,283,000 +171% 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $3,229,000 +$850,000 +36% 31 Dec 2022 10-K 12 Mar 2024 2023 FY
Q3 2022 $2,263,000 +$350,000 +18% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $1,679,000 +$232,000 +16% 30 Jun 2022 10-Q 15 Aug 2022 2022 Q2
Q1 2022 $750,000 -$373,000 -33% 31 Mar 2022 10-Q 10 May 2022 2022 Q1
Q4 2021 $2,379,000 +$83,000 +3.6% 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $1,913,000 +$557,000 +41% 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 $1,447,000 +$711,000 +97% 30 Jun 2021 10-Q 11 Aug 2021 2021 Q2
Q1 2021 $1,123,000 31 Mar 2021 10-Q 12 May 2021 2021 Q1
Q4 2020 $2,296,000 +$1,435,000 +167% 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q3 2020 $1,356,000 30 Sep 2020 10-Q 12 Nov 2020 2020 Q3
Q2 2020 $736,000 30 Jun 2020 10-Q 03 Sep 2020 2020 Q2
Q4 2019 $861,000 31 Dec 2019 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.